UBXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:25):

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging...

Stats
本日の出来高	27 330.00
平均出来高	90 258.00
時価総額	25.43M
EPS	$0 ( 2024-04-03 )
次の収益日	( $-0.570 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0.00500 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Nguyen Alexander Hieu	Buy	30 000	Stock Option (Right to Buy)
2024-03-26	Nguyen Alexander Hieu	Buy	20 000	Common Stock, $0.0001 par value
2024-02-02	Ghosh Anirvan	Sell	680	Common Stock, $0.0001 par value
2024-01-30	Ghosh Anirvan	Sell	1 183	Common Stock, $0.0001 par value
2023-11-02	Ghosh Anirvan	Sell	589	Common Stock, $0.0001 par value

INSIDER POWER
55.05
Last 99 transactions
Buy: 2 792 498 \| Sell: 401 244

ボリューム相関

長: 0.09 (neutral)

短: -0.05 (neutral)

Signal:(50.941) Neutral

UNITY Biotechnology Inc 相関

10 最も正の相関
XLRN	0.938
BRACU	0.938
NVCN	0.934
LX	0.931
ATRS	0.924
SY	0.924
ATCX	0.923
PUCK	0.919
GXII	0.919
OVID	0.918

10 最も負の相関
NAKD	-0.928
AHPI	-0.923
AMGN	-0.908
PROC	-0.906
GRPH	-0.905
GRIN	-0.903
LCAP	-0.899
LAWS	-0.896
TRIT	-0.892
CYTO	-0.888

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

UNITY Biotechnology Inc 相関 - 通貨/商品

0.86
( strong )

0.81
( strong )

0.00
( neutral )

-0.75
( moderate negative )

-0.81
( strong negative )

UNITY Biotechnology Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-1.18M (0.00 %)
EPS:	$-2.70

FY	2023
収益:	$0
総利益:	$-1.18M (0.00 %)
EPS:	$-2.70

FY	2022
収益:	$236 000
総利益:	$-1.94M (-823.73 %)
EPS:	$-6.08

FY	2021
収益:	$4 784.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0109

Financial Reports:

No articles found.

UNITY Biotechnology Inc

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.